Y. Hildebrandt

发表

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients

C. Bokemeyer, J. Panse, K. Friedrichs, 2008, British Journal of Cancer.

Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2011, American journal of hematology.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

Y. Hildebrandt, N. Kröger, D. Atanackovic, 2013, Experimental hematology.

Immunophenotypic and genetic characterization of a CD8 positive Mantle Cell Lymphoma in a patient with concomitant Mycosis Fungoides

Y. Hildebrandt, L. Trümper, R. Schroers, 2005, European journal of haematology.

5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity

Y. Hildebrandt, T. Luetkens, N. Kröger, 2014, Mediators of inflammation.

Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors.

Y. Hildebrandt, R. Schroers, A. Lieber, 2004, Experimental hematology.

The Local Cytokine and Chemokine Milieu within Malignant Effusions

C. Bokemeyer, Y. Hildebrandt, K. Bartels, 2008, Tumor Biology.

Antigen Expression in Multiple Myeloma Longitudinal Analysis and Prognostic Effect of Cancer-Testis

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2009 .

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2013, Human vaccines & immunotherapeutics.

NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer

C. Bokemeyer, K. Friedrichs, A. Marx, 2010, International journal of cancer.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.

C. Bokemeyer, T. Brümmendorf, Y. Hildebrandt, 2010, Leukemia research.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Journal of immunological methods.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

Y. Hildebrandt, N. Kröger, A. Zander, 2009, Blood.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Experimental hematology.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

Y. Hildebrandt, N. Kröger, D. Atanackovic, 2010, Bone Marrow Transplantation.

Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3.

Y. Hildebrandt, L. Trümper, R. Schroers, 2009, Vaccine.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Y. Hildebrandt, N. Kröger, K. Pflüger, 2013, Bone Marrow Transplantation.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

C. Bokemeyer, J. Panse, A. Marx, 2011, Haematologica.

Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2012, Clinical & developmental immunology.

Cancer‐testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma

Y. Hildebrandt, T. Luetkens, K. Bartels, 2015, British journal of haematology.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2014, Cancer Immunology, Immunotherapy.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Haematologica.

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2009, Clinical Cancer Research.

Decrease of CD4+FOXP3+ T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Psychoneuroendocrinology.

Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.

Y. Hildebrandt, L. Trümper, R. Schroers, 2007, Human immunology.

Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2008 .

Clinical Study Patients withMultiple Myeloma Develop SOX 2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2014 .

Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2011, Clinical & developmental immunology.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders

C. Bokemeyer, Y. Hildebrandt, K. Bartels, 2013, Stress.

Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma

Y. Hildebrandt, N. Kröger, T. Binder, 2012, Clinical & developmental immunology.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Y. Hildebrandt, N. Kröger, A. Zander, 2010, Blood.

Role of interleukin 16 in multiple myeloma.

C. Bokemeyer, J. Panse, A. Marx, 2012, Journal of the National Cancer Institute.